CR20150210A - Nuevos derivados de pirazina como agonistas receptores de cb2 - Google Patents
Nuevos derivados de pirazina como agonistas receptores de cb2Info
- Publication number
- CR20150210A CR20150210A CR20150210A CR20150210A CR20150210A CR 20150210 A CR20150210 A CR 20150210A CR 20150210 A CR20150210 A CR 20150210A CR 20150210 A CR20150210 A CR 20150210A CR 20150210 A CR20150210 A CR 20150210A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pirazina
- agonists
- receiving
- new derivatives
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Abstract
La invención se refiere a un compuesto de la fórmula (I): en la que de R1 a R4 tienen los significados definidos en la descripción y en las reivindicaciones. El compuesto de la fórmula (I) puede utilizarse como medicamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12196024 | 2012-12-07 | ||
| PCT/EP2013/075444 WO2014086807A1 (en) | 2012-12-07 | 2013-12-04 | Novel pyrazine derivatives as cb2 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20150210A true CR20150210A (es) | 2015-05-29 |
Family
ID=47290805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150210A CR20150210A (es) | 2012-12-07 | 2015-04-22 | Nuevos derivados de pirazina como agonistas receptores de cb2 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9512141B2 (es) |
| EP (1) | EP2928882B1 (es) |
| JP (1) | JP6322646B2 (es) |
| KR (1) | KR20150092156A (es) |
| CN (1) | CN104837830B (es) |
| AR (1) | AR093804A1 (es) |
| AU (1) | AU2013354115B2 (es) |
| BR (1) | BR112015009603A2 (es) |
| CA (1) | CA2885418A1 (es) |
| CL (1) | CL2015001318A1 (es) |
| CR (1) | CR20150210A (es) |
| CY (1) | CY1118808T1 (es) |
| DK (1) | DK2928882T3 (es) |
| EA (1) | EA025840B1 (es) |
| ES (1) | ES2621958T3 (es) |
| HK (1) | HK1208030A1 (es) |
| HR (1) | HRP20170572T1 (es) |
| HU (1) | HUE030836T2 (es) |
| IL (1) | IL237982A (es) |
| IN (1) | IN2015DN03145A (es) |
| LT (1) | LT2928882T (es) |
| MA (1) | MA38217B1 (es) |
| MX (1) | MX2015006036A (es) |
| PE (1) | PE20151060A1 (es) |
| PH (1) | PH12015501072B1 (es) |
| PL (1) | PL2928882T3 (es) |
| PT (1) | PT2928882T (es) |
| RS (1) | RS55951B1 (es) |
| SG (1) | SG11201504011UA (es) |
| SI (1) | SI2928882T1 (es) |
| TW (1) | TW201427960A (es) |
| UA (1) | UA116894C2 (es) |
| WO (1) | WO2014086807A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY176797A (en) | 2013-03-07 | 2020-08-21 | Hoffmann La Roche | Novel pyrazol derivatives |
| WO2014154612A1 (en) | 2013-03-26 | 2014-10-02 | F. Hoffmann-La Roche Ag | Novel pyridine derivatives |
| RS56313B1 (sr) | 2013-05-02 | 2017-12-29 | Hoffmann La Roche | Derivati pirolo[2,3-d]pirimidina kao agonisti cb2 receptora |
| TR201809417T4 (tr) | 2013-05-02 | 2018-07-23 | Hoffmann La Roche | Cb2 reseptör agonistleri olarak purin türevleri. |
| SI3483163T1 (sl) | 2013-09-06 | 2021-11-30 | F. Hoffmann-La Roche Ag | derivati triazolo(4,5-d)pirimidina kot antagonisti receptorja cb2 |
| CR20160448A (es) * | 2014-04-04 | 2016-12-14 | Hoffmann La Roche | Nuevos derivados de piridina |
| ES2787855T3 (es) * | 2015-12-09 | 2020-10-19 | Hoffmann La Roche | Derivados de fenilo como agonistas del receptor canabinoide 2 |
| EP3642200B1 (en) | 2017-06-20 | 2023-05-03 | F. Hoffmann-La Roche AG | Pyridine derivatives |
| WO2020002270A1 (en) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
| BR112020025013A2 (pt) * | 2018-06-27 | 2021-03-23 | F. Hoffmann-La Roche Ag | novos compostos de piridina e pirazina como inibidores do receptor 2 de canabinoide |
| WO2022128050A1 (en) | 2020-12-14 | 2022-06-23 | Symrise Ag | Medicament for fighting inflammation and pain |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629346B2 (en) * | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| CA2664621A1 (en) * | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | Pyrazine-2-carboxamide derivatives |
| WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
-
2013
- 2013-12-04 SI SI201330591A patent/SI2928882T1/sl unknown
- 2013-12-04 IN IN3145DEN2015 patent/IN2015DN03145A/en unknown
- 2013-12-04 UA UAA201506212A patent/UA116894C2/uk unknown
- 2013-12-04 RS RS20170313A patent/RS55951B1/sr unknown
- 2013-12-04 PT PT137995452T patent/PT2928882T/pt unknown
- 2013-12-04 EA EA201590827A patent/EA025840B1/ru not_active IP Right Cessation
- 2013-12-04 MX MX2015006036A patent/MX2015006036A/es unknown
- 2013-12-04 JP JP2015545985A patent/JP6322646B2/ja active Active
- 2013-12-04 PL PL13799545T patent/PL2928882T3/pl unknown
- 2013-12-04 SG SG11201504011UA patent/SG11201504011UA/en unknown
- 2013-12-04 AU AU2013354115A patent/AU2013354115B2/en not_active Ceased
- 2013-12-04 US US14/648,399 patent/US9512141B2/en not_active Expired - Fee Related
- 2013-12-04 PE PE2015000736A patent/PE20151060A1/es not_active Application Discontinuation
- 2013-12-04 BR BR112015009603A patent/BR112015009603A2/pt not_active Application Discontinuation
- 2013-12-04 HU HUE13799545A patent/HUE030836T2/en unknown
- 2013-12-04 ES ES13799545.2T patent/ES2621958T3/es active Active
- 2013-12-04 WO PCT/EP2013/075444 patent/WO2014086807A1/en active Application Filing
- 2013-12-04 DK DK13799545.2T patent/DK2928882T3/en active
- 2013-12-04 LT LTEP13799545.2T patent/LT2928882T/lt unknown
- 2013-12-04 CN CN201380063228.9A patent/CN104837830B/zh not_active Expired - Fee Related
- 2013-12-04 KR KR1020157014961A patent/KR20150092156A/ko not_active Application Discontinuation
- 2013-12-04 EP EP13799545.2A patent/EP2928882B1/en active Active
- 2013-12-04 MA MA38217A patent/MA38217B1/fr unknown
- 2013-12-04 CA CA2885418A patent/CA2885418A1/en not_active Abandoned
- 2013-12-05 AR ARP130104504A patent/AR093804A1/es unknown
- 2013-12-06 TW TW102144989A patent/TW201427960A/zh unknown
-
2015
- 2015-03-26 IL IL237982A patent/IL237982A/en not_active IP Right Cessation
- 2015-04-22 CR CR20150210A patent/CR20150210A/es unknown
- 2015-05-14 PH PH12015501072A patent/PH12015501072B1/en unknown
- 2015-05-15 CL CL2015001318A patent/CL2015001318A1/es unknown
- 2015-09-08 HK HK15108717.8A patent/HK1208030A1/xx not_active IP Right Cessation
-
2017
- 2017-04-07 CY CY20171100418T patent/CY1118808T1/el unknown
- 2017-04-10 HR HRP20170572TT patent/HRP20170572T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20130616A (es) | Amidas-2-piridina útiles como agonistas cb2 | |
| CR20150277A (es) | Piridina-2-amidas utiles como agonistas cb2 | |
| CR20150250A (es) | Nuevos derivados de piridina | |
| CR20150447A (es) | Nuevos derivados de pirazol | |
| CR20150204A (es) | Nuevos derivados de piridina | |
| CR20150210A (es) | Nuevos derivados de pirazina como agonistas receptores de cb2 | |
| CR20160076A (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA | |
| CO6430459A2 (es) | Derivados de prolina como inhibidores de catepsina | |
| CR20150440A (es) | Nuevos derivados de piridina | |
| CR20150511A (es) | Nuevos derivados de purina | |
| CR20140166A (es) | Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1 | |
| UY34523A (es) | Derivados de betulina | |
| UY35469A (es) | Moduladores de p2x7 | |
| CR20140525A (es) | Compuestos de N-alquiltriazol como antagonistas de LPAR | |
| UY34472A (es) | Derivados modificados de 4-fenil-piridina | |
| CR20140275A (es) | Triazolopiridinas sustituidas | |
| CR20150061A (es) | Compuesto de pirazolopirimidinas | |
| UY33929A (es) | Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas | |
| CR20150555A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina | |
| CO6741154A2 (es) | Compuestos de triazolopiridina | |
| BR112013025866A2 (pt) | formulações com viscosidade reduzida | |
| CR20160459A (es) | Nuevos derivados de piridina | |
| CL2018001493A1 (es) | Nuevos derivados de fenilo | |
| CR20160448A (es) | Nuevos derivados de piridina | |
| CR20150397A (es) | Composiciones herbicidas |